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Abstract 
Purpose: To examine international technology development of fibrates based on a cross-database 
quantitative patent review and to describe the evolution pathway for fibrates by means of a technology 
roadmap. 
Methods: The patent data were collected in March 2013 from United States Patent and Trademark 
Office (USPTO), European Patent Office (EPO) and China Intellectual Property Right Net (CNIPR) to 
broadly represent global patent activities.  
Results: This study selected and examined 84 patents from USPTO, 41 patents from EPO and 39 
patents from CNIPR. It showed that most of the fibrate patents were fenofibrate patents (41.67 % at 
USPTO, 46.34 % at EPO and 33.33 % at CNIPR). The number of preparation patents (44 at USPTO, 
24 at EPO and 17 at CNIPR) and combination patents (23 at USPTO, 11 at EPO and 15 at CNIPR) was 
obviously larger than other types of fibrate patents. The technology roadmap shows that new 
monomersor derivatives of fibrates can drive fibrate evolution into a new cycle of application-synthesis-
combination-preparation.  
Conclusion: This study provides a comprehensive picture of fibrate development. It will aid 
researchers, entrepreneurs, investors and policymakers to identify foci for fibrate research and ensure 
better decision-making. 
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Hypertriglyceridemia (HTG) is a major risk factor 
in many cardiovascular and cerebrovascular 
diseases, including coronary heart disease, 
stroke, atherosclerosis [1,2]. More and more 
research has revealed elevated triglyceride (TG) 
to be an independent risk factor for 
cardiovascular disease [3,4]. In China, the 
morbidity of HTG among people aged over 18 
years is 11.9 %, morbidity is increasing year by 
year and HTG is increasingly affecting younger 
and younger people [5].  
 
As the drug of first choice for reducing TG 
clinically, fibrates play important roles in 
metabolic regulation. However, more than 90 % 
of the market share in China belongs to foreign 
companies. About 10 local firms can only share 
the rest 10 % of the market. To become major 
players in fibrate industry, local pharmaceutical 
companies in China should significantly boost 
their research and development (R&D) efforts in 
fibrate technology. It is therefore critical for 
researchers and manufacturers to be aware of 
publications and patents in this field across 
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different laboratories, companies and countries 
to map the development of fibrates and of core 
and new fibrate technologies. 
 
Several studies have identified technology 
evolution through patent review [6-9]. Patents are 
often considered to be better source for the 
timely recognition of technological change than 
scientific and technical literatures [10]. 
Furthermore, a technology roadmap is more 
intuitive than traditional patent citation analysis or 
co-operation analysis. The use of a technology 
roadmap therefore makes it easier for 
researchers or investors to catch the latest 
developments in research.  
 
The patent literature on synthetic ligands for 
peroxisome proliferator-activated receptor 
(PPAR, target of fibrates) has been reviewed 
qualitatively by many researchers [11-13], 
whereas there is no literature on the evolution 
and status of international fibrate technology.  
 
This study aims to examine the international 
technology development of fibrates based on a 
cross-database quantitative patent review and to 
describe the evolution pathway for fibrates by 




Selection of databases 
 
Many researchers have applied patent analysis 
at the national level to show the evolution of, and 
latest trends in, technology [14,15]. However, 
patent analysis at the national level cannot 
provide a comprehensive overview of global 
technological development.  
 
To map the evolution of international research 
into fibrates, we chose the United States Patent 
and Trademark Office (USPTO) and the 
European Patent Office (EPO) to represent 
patent activities in developed countries and the 
China Intellectual Property Right Net (CNIPR) to 





Since not all patent applications receive 
authorisation, we believe that authorised patents 
are more representative than patent applications 
for the assessment of technology development. 
To optimise and maximise the results acquired 
from the three patent offices, we chose the same 
retrieval criteria ‘title or abstract’ at each patent 
office and used the names and synonyms of 
different fibrates as keywords. The data were 
collected in March 2013. It was anticipated that a 
proportion of the latest patents would not yet be 
available because of the lengthy patent 
application process (according to the collected 
data, it took on average between three and five 





After the data collection, we analysed fibrate 
distribution at USPTO, EPO and CNIPR 
respectively by chemical name, year, nation, 
assignee, technological type and International 
Patent Classification (IPC) code. A technology 
roadmap aiming to identify the evolution of the 
technology based on all of the patents collected 





After the systematic retrieval, we identified 84 
patents from USPTO, 41 patents from EPO and 
39 patents from CNIPR. Table 1 showed that 
most of the fibrate patents were fenofibrate 
patents (41.67 % at USPTO, 46.34 % at EPO 
and 33.33 % at CNIPR), and that patents for 
fibrates were ranked second (22.62 % at 
USPTO, 19.27 % at EPO and 30.77 % at 
CNIPR). Gemfibrozil patents were ranked third at 
USPTO and EPO with percentages of 17.86 and 
9.76 %, respectively. At CNIPR, bezafibrate, at 
12.82 %, was ranked third, followed by 
gemfibrozil (10.26 %). 
 
Figure 1 clearly shows that fibrates first emerged 
in the United States (US), and developed rapidly 
between 1985 and 2004 in both Europe and the 
US. During the 2000-2004 period, 31 patents 
received final authorisation in the US and 16 
patents received final authorisation in Europe. 
However, after 2004 the number clearly 
decreased.  
 
Fibrates in China developed in a different way. 
As a developing country, the Chinese fibrate 
industry emerged in the late 1990s and boomed 
in the 2000s. More and more patents have 
received authorisation in every five-year period 
from 1995, with a maximum of 19 successful 
applications between 2005 and 2010. 
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Table 1: Results of patent collection in different patent offices 
 
Chemical name N (%) USPTO EPO CNIPR 
Gemfibrozil 15(17.86) 4(9.76) 4(10.26) 
Fibrates* 19(22.62) 12(19.27) 12(30.77) 
Fenofibrate 35(41.67) 19(46.34) 13(33.33) 
Bezafibrate 2(2.38) 2(4.88) 5(12.82) 
Ciprofibrate 3(3.57) -- -- 
Etofibrate 1(1.19) 3(7.32) 1(2.56) 
Clofibrate 7(8.33) 1(2.44) 1(2.56) 
Etofylline clofibrate 1(1.19) -- -- 
Fenofibrate acid choline salt 1(1.19) -- 2(5.13) 
Fibrate carboxylate -- -- 1(2.56) 
Total 84 41 39 




 Figure 1: Number of authorised fibrate patents at USPTO, EPO and CNIPR by year of application 
 
Distribution analysis by nation 
 
Figure 2 reveals that in each market, the largest 
number of patents, which protect their assignees’ 
rights and interests, originate within the home 
market. European Union applicants had 30 
authorised patents in the US market and 10 in 
the Chinese market. US applicants received 18 
authorised patents in the EU market and 5 in the 
Chinese market. As at the date of our data 
retrieval, Chinese applicants had not received 
any patent authorisations for the US market or 
the Euro-market. 
 
Furthermore, Figure 3 shows that the fibrate 
patent flow from the European Union to the US 
was higher than that from the US to the 
European Union. Both the European Union and 
the US have fibrate patent flows to China, but 




Figure 2: Distribution of patents in different market 
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Distribution analysis by assignees 
 
Local companies in America and Europe were 
responsible for most of the patent applications 
(Figure 4). Foreign companies were the second 
most important actors in applications for fibrate 
patents, whereas very few institutes, universities 
or individuals applied for fibrate patents at 
USPTO and EPO. 
 
Table 2 reveals the main assignees of fibrate 
patents in the US, Europe and China. The Table 
shows that four companies received protection at 
all three offices: US-based Abbott and Pfizer, 
France’s Ethypharm and SkyePharma from the 
United Kingdom. Abbott owns the greatest 
number of patents, with an average patent age of 
11 to 15 years. 
 
Distribution analysis by technological types 
To locate key technologies, we categorised the 
patents into five technological types: application, 
synthesis, purification, combination and 
preparation (Table 3). From Table 3, we can 
easily adduce that the number of preparation 
patents and combination patents is obviously 
larger than other types of fibrate patents. 
Furthermore, two core types of fibrate patent 
(preparation of fenofibrate and combination of 
fibrates) are shown in Table 3. 
 
Technology roadmap for fibrates 
 
After analysing the distribution of technological 
type, we explored the innovation pathway of 
fibrate technology. In this part, technology road 
mapping is used to describe the technology 









From result presented above we can notice that, 
clofibrate was the first member of the fibrate 
class revealed to have an effect on regulating 
metabolism, but clofibrate also, inconveniently, 
was a potential safety hazard. Thus many new 
fibrates such as bezafibrate, gemfibrozil and 
fenofibrate, were synthesised by researchers 
based on the structure of clofibrate. However, 
strong variations existed between the different 
fibrates. Fenofibrate appeared to be more 
effective compared with bezafibrate, gemfibrozil 
and ciprofibrate [16]. As new fibrates proved to 
be more effective in reducing triglyceride with 
little adverse drug reaction, the basic technology 
for their preparation and combination developed 
rapidly. Many clinical trials with less satisfactory 
results followed, which showed no benefit 
resulted from adding fibrates to statin treatments 
[17]. These trials led to a reduction in enthusiasm 
for studies on new fibrates and their applications 
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Figure 4: Distribution of different types of assignee at USPTO, EPO and CNIPR 
 
Table 2: Analysis of the main assignees in different patent offices 
 
Assignee No. of patents/Mean age Attribution Country USPTO EPO CNIPR 
Abbott Laboratories 19/12.0 10/15.0 6/11.0 F USA 
Pfizer Inc. 11/19.4 6/20.3 1/27.0 F USA 
Ethypharm Ltd 3/14.0 4/15.3 3/11.7 F FRA 
SkyePharma PLC 3/11.7 4/11.8 1/12.0 F GBR 
Arena Pharmaceuticals Inc 2/7.5 0/- 1/9.0 F USA 
Veloxis Pharmaceuticals A/S 2/9.0 0/- 1/9.0 F DEN 
CLL Pharma 1/18.0 2/15.5 0/- F FRA 
Merck Patent GmbH 1/13.0 2/15.0 0/- F DEU 
Kotobuki Pharmaceutical Co Ltd 1/9.0 0/- 2/9.0 F JPN 
University of Columbia 4/12.5 0/- 0/- A USA 
Elan Pharma International Ltd 4/7.8 0/- 0/- F IRL 
Bayer Aktiengesellschaft 3/20.7 0/- 0/- F DEU 
Bristol-Myers Company 2/37.5 0/- 0/- F USA 
Ludwig Merckle K.G., Chem. Pharm. Fabrik 2/34.0 0/- 0/- F DEU 
Yeshiva University 2/12.0 0/- 0/- A USA 
Merz & Co GmbH & Co 0/- 2/20.5 0/- F DEU 
Anhui Research Center of Modern Chinese 
Medicine 0/- 0/- 2/7.5 R CHN 
Chengdu Diao Pharmaceutical Group Co Ltd 0/- 0/- 2/5.0 F CHN 
Note: F = Firm; R = Research Institute; A = Academia 
 




Application Synthesis Purification Combination Preparation 
U E U E C U U E C U E C 
             
Gemfibrozil 4 0 2 0 3 0 2 0 0 7 4 1 
Fibrates 2 0 2 2 0 0 13 8 11 2 2 1 
Fenofibrate 1 0 0 0 0 0 4 3 1 30 16 12 
Bezafibrate 1 1 1 1 1 0 0 0 2 0 0 2 
Ciprofibrate 0 0 2 0 0 1 0 0 0 0 0 0 
Etofibrate 0 1 0 0 1 0 0 0 0 1 2 0 
Clofibrate 3 1 0 0 0 0 4 0 1 0 0 0 
Etofylline clofibrate 1 0 0 0 0 0 0 0 0 0 0 0 
Fenofibrate acid 
choline salt 0 0 1 0 1 0 0 0 0 0 0 1 
Fibrate carboxylate 0 0 0 0 1 0 0 0 0 0 0 0 
Total 12 3 8 11 7 1 23 11 15 44 24 17 
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      Figure 5: Technology roadmap of fibrates 
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However, as the use of fenofibrate in the US 
increased at more than double the rate of the 
increase in statin use between 2002 and 2009, 
researchers maintained their enthusiasm for 
fenofibrate preparation [18]. This led to a 
continuous increase in the number of preparation 
patents. Moreover, as time went by, the fact that 
TG is an independent risk factor for 
cardiovascular disease (CVD), especially stroke, 
was proven by clinical trials worldwide [19-21]. 
These trials drew researchers’ attention back to 
fibrates and thus led to more the appearance of 
new preparations with high bioavailability. 
Meanwhile, developing countries, realising the 
importance of fibrates, began to follow the fibrate 
pathway from the synthesis stage.  
 
As a result, we have identified the technology 
trends and foci of fibrates: 
 
• At the very beginning, researchers might first 
notice fibrates’ effect on metabolic regulation 
when they were exploring combinations of 
other drugs. Then in the early 1970s, they first 
attached more importance to fibrates’ 
combination patents with other metabolic 
regulatory drugs 
 
• From the 1980s, the fibrate industry focused 
on basic research, i.e. the synthesis of 
fibrates, and on the applications of fibrates. 
 
• In around 1995, the combination of fibrates 
entered a stage of rapid development 
immediately after the development of 
synthesis began to slow down. Many 
combinations were proved to be effective in 
the following decade, including statins, 
metformin, protein inhibitors and many other 
chemicals. 
 
• From 2005, the preparation of fibrates began 
to reach a mature stage. Other than for 
composition, tables or capsules, many 
preparations with high bioavailability 
appeared, such as nanoparticles and 
nanosuspensions. 
 
Recently, based on the fibrate structure, new 
derivatives and preparation were found [22]. 
Novel water-soluble derivatives of fibrates were 
synthesised and evaluated using rats. This 
showed the new derivatives to have potential as 
potent anti-hyperlipemia drugs [23]. These new 
monomers and derivatives are the driving force 
that will lead fibrate technology evolution into a 
new cycle of application-synthesis-combination-




Figure 6: Evolution pathway of fibrates 
 
In addition, the results showed that although 
fibrates first emerged in the US, the European 
Union is now the largest fibrate patent holder 
with the highest patents flows towards the other 
markets. The reasons for poor performance of 
China are suggested to be the following: (1) 
Chinese fibrate technologies are below the 
standard required to receive authorisation from 
USPTO or EPO; and (2) to apply for patents 
overseas requires ample time and money. 
Because Chinese fibrate technologies may not 
be producing much profit, researchers and drug-
makers in China give up the opportunity of 
applying to foreign patent offices. It implies that 
greater collaborative links among research 
institutes and pharmaceutical firms are 
necessary for facilitate more innovative drug 
discovery and development. 
Yu et al 




This study describes the current status and 
evolution pathway of fibrates. The result of our 
study can provide researchers, entrepreneurs, 
investors and policymakers with a complete 
picture of the development of fibrates worldwide 
and to assist them in their decision-making 
processes. By using cross-database patent 
review and technology roadmap, researchers 
can locate research foci and identify potential 
development directions; entrepreneurs and 
investors can determine orientations for new 
investment; and policymakers can draw an 
overall map of a particular developing technology 
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